Cellectar Biosciences因Iopofosine I 131在复发或难治性儿童高等级胶质瘤中获得美国食品药品管理局的稀有儿童疾病认定

美股速递
Oct 27

Cellectar Biosciences因Iopofosine I 131在复发或难治性儿童高等级胶质瘤中获得美国食品药品管理局的稀有儿童疾病认定。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10